Field Trip Health Ltd.

Field Trip Health Ltd.

Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call

TORONTO, Nov. 28, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" of “Field Trip”), a global leader in the delivery of psychedelic therapies, announced today that it now plans to release financial results for its fiscal 2023 second quarter for the three-month period ended September 30, 2022, after market close on... Read More...

Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call

Appoints Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative HealthSchedules Fiscal Second Quarter 2023 Conference Call for Tuesday, November 29, 2022, at 8:30 AM ET TORONTO, Nov. 22, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a glo... Read More...

Field Trip Health & Wellness to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics on October 11th

TORONTO, Oct. 04, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at Cantor Fitzgerald’s “Symposium on Mental Health Clinics,” taking place on Tuesday, October 11, 2022. Mujeeb Jafferi, Presi... Read More...

Field Trip Health & Wellness to Present at the H.C. Wainwright 24th Annual Global Investment Conference

TORONTO, Sept. 08, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. A recording of the fires... Read More...

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

Completed corporate reorganization on August 11, 2022 separating the drug development (“Reunion Neuroscience Inc.” or “Reunion”) and healthcare and wellness (“Field Trip Health & Wellness” or “Field Trip”) divisions into two separate public companies (the “Spinout Transaction”).Field Trip received listing approval from the TSX Venture... Read More...

Field Trip Health & Wellness Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 30, 2022, at 8:30 A.M. ET

TORONTO, Aug. 23, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 29, 2022. ... Read More...

Field Trip Health & Wellness Ltd. to Commence Trading on the TSX Venture Exchange on August 17, 2022

TORONTO, Aug. 16, 2022 -- Field Trip Health & Wellness Ltd. (the "Company" of “Field Trip”), a global leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares (the "Shares") will commence trading on the TSX Venture Exchange (“TSXV”) under the ticker symbol “FTHW” at the opening of ... Read More...

Field Trip Health Ltd. Receives Conditional Approval for Listing of Common Shares of Field Trip Health & Wellness Ltd. on the TSX Venture Exchange

– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022. – Field Trip Discovery to be renamed Reunion Neuroscience Inc., remaining listed on the NASDAQ Stock Market and Toronto Stock Exchange. TORONTO, Aug. 04, 2022 -- Field Trip Health Ltd. (TSX:... Read More...

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was... Read More...

Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into Two Publicly Traded Companies

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange.- Closing of the arrangement expected to occur in August.- Also announces closing of subscription receipt offering. TORONTO, June 29, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" ... Read More...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

TORONTO, June 23, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-founder and Executive Chairman, Ronan Levy, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a live fireside ... Read More...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET

TORONTO, June 22, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year ended March 31, 2022, after market close on Wednesday, June 29,... Read More...

Field Trip Health Ltd. Announces Increased Participation in Arrangement Financing and Postponement of Shareholder Meeting Date

TORONTO, June 14, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the "Company" or "Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it has agreed to increase its participation in the concurrent financing, in support of, and in connection with, the spin-out of ... Read More...

Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies

Transaction will create two distinct emerging leaders in the psychedelics industry, one providing personalized care and the other developing next generation psychedelic therapies. Shareholders of Field Trip will receive shares of each company. Company to host a conference call on Friday, April 29, 2022 at 8:30 a.m. ET. TORONTO, April 28, ... Read More...

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104

TORONTO, April 05, 2022 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted the Company a patent for claims related to FT-104 (informally known as “Isoprocin Glutarate”),... Read More...

Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update

Earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and 330% year over year.At December 31, 2021, Field Trip had approximately $74.5 million in unrestricted cash and cash equivalents and short-term investments.Received Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate)... Read More...

Field Trip Health Ltd. to Participate in H.C. Wainwright Bioconnect Virtual Conference in January 2022

TORONTO, Jan. 05, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-Founder and CEO, Joseph del Moral, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a virtual fireside chat a... Read More...

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality

TORONTO, Dec. 14, 2021 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced the launch of its Site Management Organization Services (“SMO Services”). The SMO Services will enable companies and researchers developing psychedelic therapi... Read More...

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications.Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the “FT-200 Group... Read More...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET

TORONTO, Nov. 02, 2021 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended September 30, 2021, after market close on Monday, November 15, 2021. Th... Read More...

Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

TORONTO, Oct. 19, 2021 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their Seattle clinic, their sixth in the United States, along with the recent opening of a location in Fredericton, NB, and the imminent opening... Read More...

Field Trip Health Announces Voting Results From the Annual General and Special Meeting of Shareholders

TORONTO, Sept. 24, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), today announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, September 24, 2021. A total of 59.09% of the issued and outstanding common shares of the Corporation were represented either in ... Read More...

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

TORONTO, Sept. 09, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depressio... Read More...

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians

The KAP Co-op program gives eligible therapists the ability to provide ketamine-assisted psychotherapy (KAP) to their patients at Field Trip Health Centers utilizing Field Trip’s medical teams for screening, prescribing and administration of ketamine.Training programs will provide both didactic and experiential training to therapists and ... Read More...

Field Trip Health Ltd. Schedules First Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, August 17, 2021 at 8:30 am ET

TORONTO, Aug. 10, 2021 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its first fiscal quarter ended June 30, 2021, after market close on Monday, August 16, 2021. The Compan... Read More...

Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP

TORONTO, July 27, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it has received final approval from The NASDAQ Stock Market LLC (“NASDAQ”) to list its common shares on the NASDAQ Global Select... Read More...

Field Trip Health Ltd. Obtains Conditional Approval to List on Nasdaq Under the Symbol “FTRP”

TORONTO, July 23, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it has received conditional approval from The NASDAQ Stock Market LLC (“NASDAQ”) to list its issued and outstanding common share... Read More...

Field Trip Health Ltd. to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

TORONTO, July 08, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Ronan Levy, Co-Founder & Executive Chairman, will take part in a panel discussion and participate in one-on-one investor meetings at the Cowe... Read More...

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Field Trip completes FY2021 as the largest vertically integrated psychedelics company positioned to be a leader in the emerging industryContinues to leverage its early mover opportunity by investing in its drug development strategy and the build out of a globally recognized brand of psychedelic-assisted therapy centersClosed FY2021 with $... Read More...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call for Friday, June 25, 2021 At 8:00 am ET

TORONTO, June 17, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year 2021 ended March 31, 2021, after market close on Thursday, June... Read More...